Diabetic Gastroparesis Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Diabetic Gastroparesis Treatment Market is Segmented By Type (Grade 2, Grade 3), By Drug Class (Gastroprokinetic Agents, Antiemetic Agents, Anti-histamines, Others), By Route of Administration (Oral, Parenteral, Nasal), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Diabetic Gastroparesis Treatment Market Size

Global Diabetic Gastroparesis Treatment Market reached US$ 3.1 billion in 2022 and is expected to reach US$ 4.2 billion by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030.

The trend such as the shift towards personalized medicine enabling individual disease characteristics specific treatment is expected to dominate the global diabetic gastroparesis treatment market.

Furthermore, the rising prevalence of diabetes, increasing geriatric population around the globe, advancements in diagnostic technologies and treatment, and increasing number of clinical trials are driving up the diabetic gastroparesis treatment market size. 

The growing research activities for treating disease using diabetic gastroparesis treatment approach and presence of establish pharmaceutical companies are some of the factors in demand from North America regions. With significant competitors EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, and others actively operating in the market.

Diabetic Gastroparesis Treatment Market Scope

For more details on this report Request for Sample

Diabetic Gastroparesis Treatment Market Dynamics

The Increasing Number of Geriatric Population to Drive the Growth of the Diabetic Gastroparesis Treatment Market

The growing elderly population is a major driving force in the worldwide diabetic gastroparesis market. Diabetes is becoming more prevalent in older population, thus leading gastroparesis cases. For instance, according to World Health Organization 2022 report, 1 out of 6 people in the world will be aged 60 years or over by 2030. At this point, the population aged 60 and up will climb from 1 billion in 2020 to 1.4 billion. 

Moreover by 2050, the world's population of persons aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is expected to treble, reaching 426 Billion. This age-associated risk significantly contributes to the demand for diagnostic tools, treatments, and therapies for diabetic gastroparesis. Thus, as the geriatic population nmuber is expected to grow the market for diabetic gastroparesis treatment will drive over the forecast period.

The Emergence of New Therapies will Drive the Diabetic Gastroparesis Treatment Market Growth

Emerging therapies are predicted to drive diabetic gastroparesis treatment. There are various drugs available to treat gastroparesis, some of which are specially designed to stimulate the stomach muscles in order to improve gastric emptying. Relamorelin, prucalopride, and aprepitant are three promising experimental pharmacologic medicines. Relamorelin is a synthetic pentapeptide ghrelin receptor agonist that has been demonstrated to increase solid gastric emptying in type 2 diabetes patients while also demonstrating delayed gastric emptying.

Prokinetic drugs, for example, can aid improve stomach emptying. Researchers are continuing to look for novel drugs to treat gastroparesis, such as Velusetrag, a new drug under development. Furthermore, Evoke Pharma stated in 2020 that the FDA approved a new medication application for Gimoti nasal spray to treat symptoms in people with acute and recurrent diabetic gastroparesis. Thus, owing to the above factors the market is expected to drive over the forecast period.

The Lack of FDA Approved Therapies for Diabetic Gastroparesis Treatment Will Hamper the Growth of the Market. 

The lack of FDA-approved medications specifically intended for the treatment or management of diabetic gastroparesis hampers market expansion significantly. This regulatory barrier restricts the availability of approved and standardized medicines, reducing treatment options for diabetic gastroparesis patients.

For instance, currently metoclopramide is the only FDA approved drug to treat gastroparesis . However, it is necessary to understand that metoclopramide is not approved specifically for diabetic gastroparesis, but rather for gastroparesis in general. Other drugs, such as domperidone, have showed promise in treating gastroparesis but are not FDA-approved for this specific illness. Thus, owing to the above factors the market is expected to face a restraint over the foreseeable future.

Diabetic Gastroparesis Treatment Market Segment Analysis

The global diabetic gastroparesis treatment market is segmented based on type, drug class, route of administration, distribution channel, and region.

Owing to the Better Effectiveness, the Gastroprokinetic Agents Segment Accounted for Approximately 34.6% of the Diabetic Gastroparesis Treatment Market Share

The gastroprokinetic agents segment is poised to dominate the diabetic gastroparesis treatment market due to effectiveness in enhancing the gastrointestinal motility and are used to treat gastroparesis. Metoclopramide a dopamine-2 (D2) receptors antagonist is the treatment of choice for gastroparesis, despite not being FDA approved for diabetic gastroparesis specifically, but it is still considered to be first line drug for treatment. In most countries, only two medications are approved or available for the treatment of gastroparesis are metoclopramide and domperidone.

Furthermore, the increasing number of clinical trial for treating diabetic gastroparesis employing gastroprokinetic agents is increasing. For instance, CinDome Pharma, Inc. is conducting a clinical trial to evaluate to evaluate the efficacy and safety of CIN-102 (Deudomperidone) in adults with diabetic gastroparesis. Currently the trial is in phase 2 and the estimated completion date for the trial is October 2024. Thus, due to gastroprokinetic agents better effectiveness the segment is expected to dominate over the forecast period.

Diabetic Gastroparesis Treatment Market Geographical Share

North America Accounted for Approximately 36.9% of the Market Share in 2022, Owing to the Rising Prevalence of Diabetes

North America, particularly the U.S., dominates the global diabetic gastroparesis treatment market due to presence of huge number of key players settled in the region, growing prevalence of diabetes, and high research activities along with developments of new therapies by major organization in the region.

The rising prevalence of diabetes is a major driver of the global diabetic gastroparesis market. As the number of people diagnosed with diabetes rises, it also increases the risk of diabetic gastroparesis. As in diabetic gastroparesis, hyperglycemia can affect stomach muscles and nerves of the interstitial cells of Cajal, which assist stomach muscles move.

For instance, according to American Diabetes Association report of 2022, approximately 37.3 Billion Americans, or 11.3% of the population had diabetes in 2019. About 283,000 people aging below 20 were diagnosed with diabetes in America. Furthermore, every year 1.4 Billion Americans are diagnosed with diabetes. Thus, owing to above factors the region is expected to grow over the forecast period.

Diabetic Gastroparesis Treatment Market Companies

The major global players in the diabetic gastroparesis treatment market include EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma, and among others. 

COVID-19 Impact Analysis

The impact of COVID-19 on the global diabetic gastroparesis treatment market is significant. COVID-19, a condition caused by infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), commonly appears as fever, cough, and shortness of breath. After experiencing gastrointestinal (GI) symptoms alone or in conjunction with lung symptoms, some patients tested positive for SARS-CoV-2. 

This could be due to GI SARS-CoV-2 infection or a systemic effect of the respiratory viral illness. COVID-19 can appear as a flare of their underlying GI condition in individuals with chronic GI illnesses such as gastroparesis, as viruses have historically been involved in exacerbations of chronic GI disorders such as gastroparesis. Thereby creating a major impact on the diabetic gastroparesis treatment market.

By Type

• Grade 2
• Grade 3

By Drug Class

• Gastroprokinetic Agents
• Antiemetic Agents
• Anti-histamines
• Others

By Route of Administration

• Oral
• Parenteral
• Nasal

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On October 26, 2020, Evoke Pharma, Inc., a specialty pharmaceutical company dedicated to GI disease treatments, and EVERSANA, a leading provider of global commercial services to the life science industry, are pleased to announce the commercial launch of Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

DMI Opinion

The Global Diabetic Gastroparesis Treatment Market is predicted to expand over the forecast period. It is defined by current trends toward personalized therapy adapted to specific disease characteristics. This market transformation is aided by the emergence of novel technologies such as CRISPR-Cas9 and RNA interference, as well as factors such as rising diabetes prevalence, a growing geriatric population, advancements in diagnostics and treatments, and increased clinical trials. 

The presence of established pharmaceutical corporations and significant competitors, particularly in North America, drives the market, along with the growing elderly population. However, the lack of FDA-approved medicines for diabetic gastroparesis treatment remains a limitation. Because of its effectiveness in improving gastrointestinal motility, the Gastroprokinetic Agents segment is expected to grow. The COVID-19 pandemic has also had major effects on the market, with GI symptoms developing as part of the disease and potentially affecting underlying diseases such as gastroparesis. Overall, the market has the potential for growth as a result of these distinct dynamics and trends.

Why Purchase the Report?

• To visualize the global diabetic gastroparesis treatment market segmentation based on type, drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diabetic gastroparesis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global diabetic gastroparesis treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies